Related Experiment Videos

Pentamidine isethionate is negative in tests for microbial mutagenicity and chromosomal breakage in vitro

T H Connor1, Z Trizna

  • 1University of Texas Health Science Center, School of Public Health, Houston 77225.

Toxicology Letters
|October 1, 1992
PubMed

Insights

Pentamidine isethionate, used for Pneumocystis pneumonia in AIDS patients, was evaluated for genetic damage. Studies found no evidence of mutagenicity or clastogenicity, indicating the drug is safe in these assays.

Area of Science:

  • Toxicology
  • Genetics
  • Pharmacology

Background:

  • Pentamidine isethionate is a critical treatment for Pneumocystis carinii pneumonia, particularly in Acquired Immunodeficiency Syndrome (AIDS) patients.
  • Assessing the genotoxic potential of essential medications is crucial for patient safety.

Purpose of the Study:

  • To evaluate the mutagenic potential of pentamidine isethionate.
  • To assess the clastogenic and mutagen-induced chromosomal breakage effects of pentamidine isethionate in human cell lines.

Main Methods:

  • Mutagenicity was tested in five Salmonella typhimurium strains (repair-deficient and repair-positive) with and without rat liver S-9.
  • Clastogenicity and chromosomal breakage were examined in five human lymphoblastoid cell lines, with and without bleomycin co-treatment.

Main Results:

  • Pentamidine isethionate showed no mutagenic activity in any Salmonella typhimurium strain.
  • No clastogenicity or increased chromosomal breakage was observed in human lymphoblastoid cell lines treated with pentamidine isethionate alone or in combination with bleomycin.

Conclusions:

  • Pentamidine isethionate is not mutagenic in bacterial assays.
  • Pentamidine isethionate does not exhibit clastogenic or mutagen-induced chromosomal breakage effects in human lymphoblastoid cell lines under the tested conditions.

Related Concept Videos